viewImugene Ltd

Imugene appoints global pharmaceutical executive to its board

Dr. Lesley Russell brings extensive pharmaceutical experience to the board including a number of cancer therapy collaborations with Teva Pharmaceuticals.

table and chairs
Imugene is advancing its promising cancer vaccine pipeline

Imugene Ltd (ASX:IMU) has appointed leading global pharmaceutical executive Dr. Lesley Russell as a non-executive director, effective April 23, 2019.

Dr. Russell has more than 25 years of international operational and leadership experience with a number of established and emerging pharmaceutical companies across multiple therapeutic areas including oncology and haematology.

READ: Imugene well-funded to progress clinical milestones

Her experience has been gained at a number of leading companies including Amgen (NASDAQ:AMGN), Eli Lilly (NASDAQ:LLY), Cephalon Inc (NASDAQ:CEPH) and Teva Pharmacaeuticals (NASDAQ:TEVA).

Dr. Russell is currently a non-executive director of AMAG Pharmaceuticals (NASDAQ:AMAG), Enanta Pharmaceuticals (NASDAQ:ENTA) and Sojournix a privately held biotechnology company.

READ: Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx

Imugene executive chairman Paul Hopper said: “Dr. Lesley Russell’s global industry knowledge and direct experience of oncology drug development and strategic joint ventures will further enhance the board’s skill mix.

“We are delighted she is joining our business and look forward to her contributions as we work to advance our promising cancer vaccine pipeline.”

Quick facts: Imugene Ltd

Price: 0.035 AUD

Market: ASX
Market Cap: $154.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read